Letter: ACE2, IBD and COVID-19-why IBD patients may be at reduced risk of COVID-19
- PMID: 33105980
- PMCID: PMC7537250
- DOI: 10.1111/apt.16063
Letter: ACE2, IBD and COVID-19-why IBD patients may be at reduced risk of COVID-19
Abstract
LINKED CONTENT
This article is linked to Taxonera et al paper. To view this article, visit
Figures
Comment on
-
2019 novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases.Aliment Pharmacol Ther. 2020 Jul;52(2):276-283. doi: 10.1111/apt.15804. Epub 2020 Jun 7. Aliment Pharmacol Ther. 2020. PMID: 32359205 Free PMC article.
References
-
- An P, Menguao J, Megyao J, et al. Protection of 318 inflammatory bowel disease patients from the outbreak and rapid spread of COVID‐19 infection in Wuhan, China. Lancet. 2020;5:525–527. - PubMed
-
- Brenner EJ, Ungaro R, Colombel JF, Kappelman MD. Secure‐IBD Database Public Data Update. https://covidibd.org. Accessed June 31, 2020.
-
- Garg M, Royce SG, Tikellis C, et al. Imbalance of the renin‐angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target? Gut. 2020;69:841‐851. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources